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Abstract 
Context: Preeclampsia is a leading cardiovascular complication in pregnancy lacking 
effective diagnostic and treatment strategies.
Objective: To investigate the diagnostic and therapeutic target  potential of the 
angiogenesis proteins, FK506-binding protein like (FKBPL) and CD44.
Design and Intervention: FKBPL and CD44 plasma concentration or placental expression 
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endothelial cell function was assessed following mesenchymal stem cell (MSC) treatment 
and in the context of FKBPL signaling.
Settings and Participants: Human samples prediagnosis (15 and 20 weeks of gestation; 
n ≥ 57), or postdiagnosis (n = 18 for plasma; n = 4 for placenta) of preeclampsia were 
used to determine FKBPL and CD44 levels, compared to healthy controls. Trophoblast or 
endothelial cells were exposed to low/high oxygen, and treated with MSC-conditioned 
media (MSC-CM) or a FKBPL overexpression plasmid.
Main Outcome Measures: Preeclampsia risk stratification and diagnostic potential of 
FKBPL and CD44 were investigated. MSC treatment effects and FKBPL-CD44 signaling in 
trophoblast and endothelial cells were assessed.
Results: The CD44/FKBPL ratio was reduced in placenta and plasma following clinical 
diagnosis of preeclampsia. At 20 weeks of gestation, a high plasma CD44/FKBPL ratio 
was independently associated with the 2.3-fold increased risk of preeclampsia (odds 
ratio = 2.3, 95% confidence interval [CI] 1.03-5.23, P = 0.04). In combination with high 
mean arterial blood pressure (>82.5 mmHg), the risk further increased to 3.9-fold (95% 
CI 1.30-11.84, P = 0.016). Both hypoxia and MSC-based therapy inhibited FKBPL-CD44 
signaling, enhancing cell angiogenesis.
Conclusions: The FKBPL-CD44 pathway appears to have a central role in the pathogenesis 
of preeclampsia, showing promising utilities for early diagnostic and therapeutic 
purposes.
Key Words: preeclampsia, angiogenesis, risk prediction, mesenchymal stem cell treatment, trophoblast cells, endo-
thelial function
Hypertensive disorders of pregnancy are a leading cause 
of maternal and neonatal morbidity and mortality (1). 
Preeclampsia, one of the most dangerous hypertensive dis-
orders of pregnancy, develops after 20 weeks of gestation 
and occurs in 2% to 8% of pregnancies (2). Preeclampsia 
is characterized by the new onset of high blood pres-
sure (≥140/90  mm Hg) on 2 separate occasions and evi-
dence of end-organ involvement, most commonly renal 
or liver, in pregnancy (3). There are 2 main phenotypes of 
preeclampsia: (i) early-onset or preterm preeclampsia diag-
nosed prior to 34 weeks of gestation and (ii) late-onset or 
term preeclampsia diagnosed from 34 weeks of gestation 
onward (4,5). There is great interest in developing bio-
markers of preeclampsia, which can predict likelihood of, 
or evolving, preeclampsia from the first to third trimester 
(6). However, poorly understood molecular regulation of 
pathogenesis has hindered the development of reliable 
biomarkers especially in relation to the late-onset and 
evolving preeclampsia (6). Clinically employed screening 
tests based on angiogenesis-related biomarkers (eg, soluble 
fms-like tyrosine kinase 1 [sFlt-1] and placental growth 
factor [PlGF]) are able to predict the onset of preeclampsia 
only a few weeks before presentation of clinically ob-
vious preeclampsia (7). Other predictive algorithms have 
been used successfully early in pregnancy between 11 and 
13 weeks of gestation based on maternal characteristics, 
uterine artery pulsatility index and angiogenic factors such 
as PlGF and PAPP-A (8). However, these are mainly ef-
fective at predicting early-onset or preterm preeclampsia. 
Therefore, risk stratification strategies for late-onset 
preeclampsia as well as evolving preeclampsia between the 
second and third trimester of pregnancy, are lacking. This is 
particularly important as stratifying pregnancies at risk of 
preeclampsia has been associated with improved pregnancy 
outcomes (9) and appears cost-effective, even a few weeks 
before the clinical onset of disease (10).
Although low-dose aspirin has been effective at 
preventing early-onset preeclampsia (11), the only treat-
ment of established preeclampsia is delivery of the pla-
centa, which necessitates delivery of the baby, frequently 
at preterm gestations. Mesenchymal stem cells (MSCs) 
are emerging as an attractive treatment in various diseases 
and injury models due to their low immunogenicity, easy 
cultivation, and expansion in vitro. In preclinical models 
of preeclampsia, MSCs demonstrated therapeutic effi-
cacy (12,13), likely through paracrine signaling; however, 
the underlying mechanisms are not yet well understood 
(14,15).
FK506-binding protein like (FKBPL) is a peptidyl prolyl 
cis trans isomerase, which belongs to the immunophilin pro-
tein group with important roles in vascular diseases (16). 
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levels secreted from endothelial cells (17). As such, FKBPL 
plays an important role in both developmental and patho-
logical angiogenesis; FKBPL knockout mice were embry-
onically lethal whereas FKBPL heterozygous knockdown 
mice showed signs of impaired vascular integrity (18). 
Furthermore, FKBPL also appears to regulate “stemness”; 
with high levels promoting differentiation, while low levels 
increased stem cell–like characteristics (19-21). Inhibition 
of angiogenesis and stem cell signaling by FKBPL ap-
pears to be dependent on CD44; knockdown of CD44 
abrogates the FKBPL-mediated inhibition of angiogenesis 
and binding assays suggest an interaction between the 2 
proteins (17,22). There is also evidence for targeting the 
signal transducer and activator of transcription 3–nuclear 
factor kappa B inflammatory pathway (20). The potential 
of FKBPL as a prognostic biomarker has been previously 
discussed in relation to other pathologies such as cancer 
(23-25), but not in the context of preeclampsia.
As a critical inhibitor of angiogenesis, we hypothesized 
that the FKBPL-CD44 pathway has an important role in 
the pathogenesis of preeclampsia, which could be utilized 
for diagnostic and therapeutic purposes. To address this 
hypothesis, we demonstrated that FKBPL is differentially 
secreted early in pregnancy (weeks 15 and 20 of gestation) 
in women who proceeded to develop preeclampsia. At 20 
weeks of gestation, the CD44/FKBPL ratio in combination 
with mean arterial blood pressure (MAP) was capable of 
predicting a four-fold increased risk of preeclampsia in 
nulliparous pregnant women; most of the pregnancies in 
our cohort proceeded to develop late-onset preeclampsia. 
The CD44/FKBPL ratio was also capable of diagnosing 
preeclampsia and was differentially expressed in placentae 
affected by preeclampsia. Further studies indicated that 
FKBPL regulates trophoblast and endothelial cell func-
tion important for spiral uterine artery (SUA) develop-
ment. Hypoxia and MSCs are capable of inhibiting the 
FKBPL-CD44 anti-angiogenic pathway.
Materials and Methods
Enzyme-linked immunosorbent assay of human 
plasma and isolated MSCs
Ethylenediamine tetra-acetate plasma samples obtained 
from whole blood were centrifuged for 15 min at 2000 rpm 
at 4°C. Upon separation, plasma was stored at −80°C until 
further usage. For CD44, the inter-assay coefficient of vari-
ability (CV) was 6.9% and the average intra-assay CV 
% was 3.9%. The average intra- and inter-assay CV for 
FKBPL was 5.5% and 17.1%, respectively. Samples were 
assayed in duplicates and only included if CV percentage 
was below 15. Even though the inter-assay CV for FKBPL 
was high, we ensured that the investigators were blinded to 
the identity of the samples, and on each plate we had similar 
numbers of preeclampsia and control samples at each time 
point. Each enzyme-linked immunosorbent assay plate in-
cluded a randomized selection of preeclampsia and control 
samples labeled with unique identifiable codes provided by 
the biobank, which were blinded to both operators. Plasma 
was diluted 2-fold for FKBPL (Cloud-Clone Corp., USA) or 
40-fold for CD44 (Abcam, UK) using standard diluent pro-
vided by the kit. Human MSCs were isolated from abdom-
inal fat tissue removed from women during C-section and 
cultured for 48 h as described previously (26) before me-
dium was collected and secreted FKBPL measured. Human 
plasma samples used were from two separate cohorts of 
pregnant women with established clinical preeclampsia and 
normotensive controls, pregnant women with prediagnosis 
of clinical preeclampsia collected at 15 and 20 weeks of 
gestation, and healthy controls of the same gestational age. 
All studies with human samples were approved by the local 
institutional review boards and written informed consent 
was obtained from all participants.
Immunofluorescence staining of placental tissue
Women considered to be at high risk of preeclampsia and 
their matched controls provided written informed con-
sent at the Royal Jubilee Maternity Hospital (27). Ethical 
approval was obtained from the National Health Service 
Health Research Authority (ORECNI, 14/NI/1068). 
Ethical approval was also obtained from the School of 
Medicine, Dentistry and Biomedical Sciences (Queen’s 
University Belfast). Following delivery, each placenta was 
collected and processed by the Northern Ireland Biobank 
(28). Preeclampsia samples (n = 4) were paired 1-to-1 with 
normotensive control samples (n = 4) based on age and 
body mass index (BMI). The samples were also matched 
for gestational age. Placental slides for immunofluorescence 
analysis were prepared using fresh frozen placental tissue 
near the umbilical cord and stained for FKBPL (Cat. no.: 
10060-1-AP; Proteintech, UK) and CD31 (Cat. no: 351-
004; Synaptic Systems, Germany). For the immunofluor-
escence analysis, 4 random fields of view were selected to 
evaluate the mean fluorescence intensity in each sample/
slide and quantify protein expression as previously de-
scribed (29). Background was acquired from a vacant area 
of the labeled section and subtracted from the raw images 
to eliminate background noise.
Cell culture
A total of 5 cell lines were used in subsequent investiga-








niversity of Technology, Sydney user on 04 February 2021
The Journal of Clinical Endocrinology & Metabolism, 2021, Vol. 106, No. 1 29
75  cm2 tissue culture flasks (Nunc; Thermoscientific, 
Denmark) at 37°C, in an atmosphere of 5% CO2 and 
95% air (Laboratory Technical Engineering, UK). All 
cell lines were authenticated by short tandem repeat pro-
filing performed by the suppliers and routinely tested for 
Mycoplasma.
 1. Human placenta choriocarcinoma (BeWo) (ATCC, USA) 
were maintained in DMEM/F12 (ThermoFisher, UK) 
medium supplemented with 10% fetal bovine serum 
(FBS) (ThermoFisher, UK).
 2. Human placenta choriocarcinoma (Jar) (ATCC, USA) 
were maintained in RPMI-1640 medium supplemented 
with 10% FBS.
 3. Human umbilical vein endothelial cells (HUVECs) 
(ATCC, USA) were maintained in endothelial cell growth 
medium MV2 (Promocell, Germany), supplemented 
with low serum growth supplement containing the 
following: 5% fetal calf serum, epidermal growth factor 
5  ng/mL, basic fibroblast growth factor 10  ng/mL, 
insulin-like growth factor 20 ng/mL, vascular endothelial 
growth factor 0.5  ng/mL, ascorbic acid 1  μg/mL and 
hydrocortisone 0.2  μg/mL, on gelatine-coated tissue 
culture flasks.
 4. ACH-3P cells were kindly donated by Professor Gernot 
Desoye (Graz Medical University, Austria). Briefly, 
immortalized AC1-1 cells and primary trophoblast cells 
were fused as previously described (30) to form a unique 
ACH-3P cell line. Immortalized first-trimester cells were 
maintained in Hams F-12 medium (Thermofisher, UK) 
supplemented with 10% FBS. All experiments with 
ACH-3P cells were carried out at the Graz Medical 
University.
 5. Primary human bone marrow–derived MSCs, which 
met the criteria of the International Society for Cellular 
Therapy (31), were obtained from the Institute for 
Regenerative Medicine at Texas A&M Health Science 
Center, Baylor, Scott and White Hospital (Temple, Texas, 
USA). MSCs were maintained in αMEM (Thermo 
Fisher Scientific, UK) supplemented with 16.5% heat-
inactivated FBS, 50 µg/mL penicillin-streptomycin , and 
4 mM L-glutamine (Thermo Fisher Scientific, UK) and 
used up to passage 7 as previously described (32).
Treatment with MSCs
MSCs were seeded in 6 well plates in prescribed supple-
mented media for HUVEC, BeWo, and Jar at a ratio of 1 
MSC to every 5 HUVEC, BeWo, or Jar. The cells were al-
lowed to adhere and conditioned in the prescribed media 
for 24 h under 21% O2 conditions. Prior to the day of ex-
perimentation, the conditioned medium was aspirated off, 
collected, and centrifuged for 5 min at 1200 rpm to remove 
cell debris. Conditioned media was then pre-equilibrated to 
21% (normoxia) or 1% (hypoxia) O2 prior to being used 
for other downstream experiments.
FKBPL plasmid overexpression
Cells were grown to 50% (HUVECs) or 60% to 70% 
(BeWo or Jar) confluence before being transiently trans-
fected with 1µg FKBPL plasmid (Sino Biological, PA, USA), 
or equivalent amounts of control pCMV plasmid (Sino 
Biological, USA) using EndoFectin (GeneCopoeia, USA). 
Following a 24-h transfection, the cells were trypsinized 
and reseeded for the tubule formation assay. Protein lysates 
were also collected following 24 h of transfection and sub-
jected to Western blotting analysis.
Clonogenic assay
To assess the ability of BeWo and Jar to form clones, 1000 
and 2000 cells were seeded in 6 well plates, incubated for 
16 to 18  days in 21% or 1% O2. Following incubation, 
media were aspirated and colonies washed prior to being 
stained with 0.4% crystal violet. Colonies containing 50 
cells or more were manually counted and identified as 
“holoclones,” “meroclones,” or “paraclones” according to 
their morphologies using a DMI8 inverted light microscope.
Tubule formation assay
To assess the ability of HUVECs to form tube-like structures, 
7×105 HUVEC were resuspended in 500 μL MSC-CM, or 
control media, and stained with calcein (2µg/mL) (Thermo 
Fisher Scientific, UK) prior to being seeded on phenol red 
free reduced-growth factor Matrigel under 21% and 1% 
O2 for 6 h. Tubule formation was imaged by randomly cap-
turing 6 images per well using a DMI8 inverted florescence 
microscope. Total tube length was quantified using Image J 
software (NIH, USA).
Wound scratch migration assay
To investigate the effects of MSC conditioned media on 
trophoblast and endothelial wound closure under 21% 
and 1% O2, a wound scratch migration assay was set 
up as described before (32). HUVECs and BeWo were 
seeded at a cell density of 5×104 cells, and Jar were 
seeded at a cell density of 3×104 cells. They were allowed 
to reach confluence at 37°C in 5% CO2. A  single ver-
tical “scratch” wound was made using a sterile P200 tip 
from the top to bottom of each well, running through 
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to remove cell debris and 500 µL serum free cell growth 
medium was added to each well. The wound area of each 
well just above and just below the horizontal line was 
imaged using a DMI8 inverted light microscope, along 
with tile scan coordinates available with AxioVision Rel. 
4.8 software.
Following baseline measurement, serum-free media 
were replaced with 500 µL MSC-conditioned medium and 
prescribed cultivation media or serum free media (pre-
equilibrated in 21% or 1% O2). Plates were incubated 
at 37°C in 21% or 1% O2 for 24 h before wound areas 
were reimaged. The area of the wound site at baseline 
and at 24 h was measured using ImageJ v1.48. The values 
obtained were used to calculate the percentage of wound 
closure over 24 h.
Real-time polymerase chain reaction
Ribonucleic acid (RNA) from placental samples was 
extracted using Qiagen RNeasy kit (Qiagen, Hilden, 
Germany) according to the manufacturer’s instruc-
tions. Cell-line RNA was extracted using TRIzol™ 
reagent (Thermo Fisher Scientific, UK) as previously 
described (17) and reverse transcribed using custom 
made master mix (Thermo Fisher Scientific, UK). 
Complementary deoxyribonucleic acid was prepared 
for real-time quantitative polymerase chain reac-
tion (qPCR) using the Roche Lightcycler Probes 480 
Master kit (Roche, USA) and Roche Realtime Ready 
TaqMan gene expression mono hydrolysis probes for 
human FKBPL, CD44, and 18S (Roche, USA). The 
resulting crossing points were calculated using the 
Roche LightCycler 480 software and quantified using 
the standard curve efficiency. Sample crossing point 
values were corrected to 18S expression. Data analysis 
was carried using the ΔΔCT method.
Western blotting
Alongside  migration and invasion assays, BeWo, Jar, 
HUVEC, and ACH-3P cell lysates were harvested using 
radioimmunoprecipitation assay buffer (SantaCruz 
Biotechnology, USA) supplemented with protease and 
phosphatase inhibitor cocktails (Roche, UK). Cell lys-
ates were reduced in 4× and 10× Bolt LDS Sample buffer 
(ThermoFisher, UK) and subjected to Western blotting. 
Blots were probed with specific primary antibody and ap-
propriate HRP-linked secondary immunoglobulin G (Cell 
signaling, UK) at 1:10 000. The membrane was imaged with 
G:Box (SynGene, India) after incubation using either West 
Dura or Femto chemiluminescent (ThermoFisher, UK). 
Antibodies CD44H (R&D Systems, cat: BBA10); FKBPL 
(Proteintech, USA cat: 10060-1-AP); anti-glyceraldehyde 
3-phosphate dehydrogenase (GAPDH) (cell signaling, UK, 
cat: G9545); all antibodies were used at 1:1000 unless 
otherwise stated.
Statistical analysis
The data were analyzed using a 2-tailed t-test or 1-way 
or 2-way analysis of variance (ANOVA), followed by 
Sidak’s or Tukey’s multiple comparisons tests and ad-
justed P values reported. Values were considered stat-
istically significant if P < 0.05. Experiments involving 
cell lines and primary cells included the results from a 
minimum of 3 independent repeats, and the results were 
expressed as the mean ± the standard error of the mean 
(SEM). Analysis was performed using Prism 5 software 
(GraphPad Software, La Jolla, CA, USA). The statistical 
analyses of the results in relation to FKBPL, CD44, and 
the clinical characteristics of Cohort 3, the SCOPE Cork 
subset (33) were performed using SPSS 20.0 (IBM, New 
York, USA). After initial testing for normality (Shapiro-
Wilks test), differences between groups (preeclampsia vs 
controls) were tested using independent samples t-test 
or Mann-Whitney, where appropriate. Preeclampsia 
and control samples were matched for age and BMI. 
Receiver operating characteristic (ROC) curve analysis 
was used to obtain cut-off values for primary variables 
(CD44/FKBPL ratio and MAP) measured at 20 weeks 
gestation. Participants were stratified into either a group 
with low levels (below the cut-off) or a group with high 
levels (above the cut-off value) of the parameters in ques-
tion. The contribution of the CD44/FKBPL ratio to the 
risk of preeclampsia development was assessed using 
binary logistic regression, which included age, BMI, 
weight change and MAP as the possible confounders. 
Multinomial logistic regression was used to test the com-
bined effect of the CD44/FKBPL ratio and MAP on the 
risk of developing preeclampsia. Significance was set at 
P < 0.05.
Study approvals
For all human samples used in this study, written in-
formed consent was received from participants prior to 
inclusion in the study. Studies involving human samples 
were also approved by local institutional ethics review 
boards. All personal details were anonymized, and par-
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Results
The diagnostic potential of the FKBPL-CD44 
pathway after the onset of clinical preeclampsia
Using patients’ samples from the Cohort 1 (Table 1) fol-
lowing clinical diagnosis of preeclampsia, we meas-
ured plasma FKBPL and CD44 concentration (n = 18, 
preeclampsia; n = 14, control) as well as secreted 
FKBPL from MSCs isolated from pregnant women with 
preeclampsia (n = 3) and normotensive controls (n = 3). 
Plasma FKBPL concentration was increased in women 
with preeclampsia compared to controls (Fig. 1A; 0.81 ng/
mL ± 0.018 SEM vs 0.76  ng/mL ± 0.011 SEM, P < 0.05) 
whereas plasma CD44 concentration was decreased in 
the same samples (Fig.  1B; 85.1  ng/mL ± 4.2 SEM vs 
104.7  ng/mL ± 4.9 SEM, P  < 0.01). The CD44/FKBPL 
ratio was also significantly reduced in preeclampsia cases 
compared to controls (Fig.  1C; 105.3  ng/mL ± 5.5 SEM 
vs 136.3  ng/mL ± 5.2, P  < 0.001). Statistical significance 
was maintained (P = 0.02) when the CD44/FKBPL ratio 
was adjusted for differences in gestational age between 
the preeclampsia and control groups (Table  1), using lo-
gistic regression. A cut-off value based on the ROC curve 
(area under the curve [AUC] = 0.84, P = 0.001) of less than 
134.6 (sensitivity 94.4 and specificity 71.4) was associated 
with a 3.3-fold increase in likelihood ratio. There were no 
differences in age (P = 0.65), BMI (P = 0.34), or gravidity 
(P = 0.74) between groups; however, gestational age was 
lower (P = 0.001) in the preeclampsia group (Table 1).
Similarly, secretion of FKBPL from adipose-tissue isolated 
MSCs from women with preeclampsia was increased com-
pared to controls (0.562 ng/mL ± 0.012 SEM vs 0.377 ng/
mL ± 0.002 SEM; P < 0.001; Fig. 1D). The 2 groups of women 
(controls vs preeclampsia) were matched for age (26.7 ± 3 vs 
27 ± 7, P = 0.8), BMI (36.6 ± 6.2 vs 32.3 ± 3.0, P = 0.7) and 
gestational age (38.1 ± 0.85 vs 32.6 ± 5.1, P = 0.1).
In light of FKBPL’s critical role in developmental, 
physiological, and pathological angiogenesis as an anti-
angiogenic protein (18) via CD44 (17), we investigated 
both FKBPL and CD44 expression in placental samples 
from women with and without preeclampsia (Cohort 2, 
Table 2). Placental expression of FKBPL, CD44, intercel-
lular adhesion molecule (ICAM), and vascular cell adhe-
sion molecule (VCAM) from women with preeclampsia 
were compared to their normotensive controls (matched 
for age, BMI, and gestational age; Table 2). The expression 
of FKBPL was observed in both syncytiotrophoblasts and 
blood vessels (Fig. 2A pictures inset). Our results demon-
strated increased FKBPL protein expression (>1.5-fold) in 
preeclampsia cases compared to controls (Fig. 2A; P < 0.05, 
n = 4). The endothelial cell marker, CD31, was not signifi-
cantly different between preeclampsia and control samples 
(Fig. 2B; P = 0.27; n = 4 [preeclampsia] and n = 3 [control]). 
At the messenger RNA (mRNA) level, using RNA lysates 
from the same placental samples, we confirmed increased 
FKBPL mRNA expression and a concomitant reduction in 
its target gene, CD44 (Fig. 2C; FKBPL: P < 0.01; CD44: 
P < 0.05; n = 3). The presence of endothelial dysfunction 
in preeclampsia has been well established (34), which was 
confirmed in our cohort by increased expressions of the 
endothelial dysfunction markers, VCAM-1 and ICAM-1 
(Fig. 2D; VCAM-1: P < 0.01; ICAM-1: P ˂ 0.001; n = 3).
The predictive potential of the FKBPL-CD44 
pathway before the onset of clinical preeclampsia
Having shown that FKBPL is regulated by established 
preeclampsia, we wanted to investigate the predictive bio-
marker potential of FKBPL and CD44 using plasma sam-
ples from nulliparous women with singleton pregnancies 
at 15 and 20 weeks of gestation from Cohort 3 (Table 3) 
(33). There was no difference in CD44 plasma concen-
tration (115.9 ± 24.5 standard deviation [SD], n = 60 vs 
121.7 ± 28.7 SD, n = 60; P = 0.23). However, the FKBPL 
plasma concentrations were significantly lower (0.72 
[0.52-1.10], n = 61 vs 1.0 [0.59-1.30], n = 59; P = 0.03), 
at 15 weeks of gestation in women who proceeded to de-
velop preeclampsia. At 20 weeks of gestation, both CD44 
(127.5 ng/mL ± 30.2 SD, n = 62 vs 115.3 ng/mL ± 26.4 SD, 
n = 60, P = 0.02) and FKBPL plasma concentrations (0.65 
[0.44-1.08], n = 57 vs 0.89 [0.61-1.16], n = 58; P = 0.01) 
were higher and lower in the preeclampsia group com-
pared to controls, respectively. When CD44 and FKBPL 
were combined as the CD44/FKBPL ratio, the differences 
between preeclampsia and control groups demonstrated 
an increase in the plasma CD44/FKBPL ratio (15th week: 
Table 1. Clinical characteristics of normotensive pregnancies 






Age (year) 31.77 ± 2.20 32.23 ± 3.79 0.66
BMI (kg/m2) 30.97 ± 6.59 34.01 ± 4.98 0.16
Gestational age 39.00 ± 2.77 34.50 ± 2.71 0.001
Gravidity 1.5 (1-5) 2 (1-1) 0.73
Term pregnancies 1.5 (1-3) 1 (0-4) 0.11
Preterm pregnancies 0 (0-1) 1 (0-2) 0.016
Previous abortions 0 (0-3) 0 (0-1) 0.29
Number of living 
children
1.5 (1-3) 1.5 (1-5) 0.77
Age, BMI, and gestational age are presented as mean ± SD; all other values 
are presented as median with min-max range. Student t-test and Fischer test. 
Bolded P-values indicates a significant difference between the two groups.
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143.1 [113.2-259.2], n = 57, 128.8 [91.2-176.1], n = 56; 
P = 0.02; 20th week: 181.1 [121.3-302.4], n = 54 vs 143.1 
[101.3-176.3], n = 55; P = 0.004, Table 3).
Based on the ROC curve analysis, we were able to deter-
mine a suitable cut-off point for the CD44/FKBPL ratio of 
143.6 (AUC = 0.659, P = 0.004; sensitivity = 0.7, specifi-
city = 0.51) or 155.1 (sensitivity = 0.6 and specificity = 0.6) 
for prediction of the risk of preeclampsia at 20 weeks of 
gestation. Using this cut-off point, a univariate logistic re-
gression model demonstrated, that women with a CD44/
FKBPL ratio above 143.6 or 155.1 had a 2.5- or 2.4-fold 
increased risk of developing preeclampsia later in preg-
nancy (P = 0.02, P = 0.03), respectively. Multivariate lo-
gistic regression models using BMI, age, weight change, and 
MAP as confounders, demonstrated that the CD44/FKBPL 
ratio persisted to be associated with preeclampsia inde-
pendently of BMI, age, weight change, and MAP (143.6: 
odds ratio [OR] = 2.3 95% confidence interval [CI] 1.03-
5.2, P = 0.04; 155.1: OR = 2.3 95% CI 1.05-5.2, P = 0.04; 
Tables 4 and 5). The combined effect of the CD44/FKBPL 
ratio and MAP (cut-off = 82.5  mmHg; AUC = 0.648, 
P = 0.004; sensitivity = 0.62, specificity = 0.59), on the risk 
of developing preeclampsia was investigated using multi-
nomial logistic regression models. Participants were div-
ided into 4 groups: (i) low-risk (reference) group—women 
with a low plasma CD44/FKBPL ratio (˂143.6 or 155.1) 
and MAP (˂82.5  mmHg), (ii) high-risk group (CD44/
FKBPL > 143.6 or 155.1 and MAP > 82.5  mmHg), (iii) 
Figure 1. Secreted FKBPL and CD44 from plasma and primary mesenchymal stem cells are increased and decreased, respectively, in preeclampsia. 
(A) Plasma FKBPL is increased in pregnant women with preeclampsia (n = 18) compared to controls (n = 14); 2-tailed unpaired t-test. (B) Plasma CD44 
is decreased in pregnant women with preeclampsia (n = 18) compared to controls (n = 14); 2-tailed unpaired t-test. (C) CD44/FKBPL ratio is decreased 
in pregnant women with preeclampsia (n = 18) compared to controls (n = 14); 2-tailed unpaired t-test. (D) Secreted FKBPL concentration was higher 
in cultured MSCs isolated from abdominal fat tissue in preeclampsia (n = 3) vs. controls (n = 3). FKBPL secretion in preeclampsia was adjusted to the 
number of MSC; 2-tailed unpaired t-test. Data are presented as mean ± SEM. *P < 0.05; ***P < 0.001.
Table 2. Maternal baseline characteristics from women 




(n = 4) 
P 
value 
BMI 32.0 ± 7.6 29.7 ± 2.8 0.38 
Age 34.0 ± 4.3 31.8 ± 6.2 0.42 
Gestational week 
(weeks ± days) 
36.7 ± 1.8 37.9 ± 2.6 0.36
First trimester right hand sBP 130.8 ± 3.6 125.1 ± 7.7 0.17 
First trimester right hand dBP 90.6 ± 13.9 73.5 ± 22.3 0.18 
First trimester left hand sBP 133.8 ± 6.6 125.1 ± 9.8 0.07 
First trimester left hand dBP 91.3 ± 10.2 81.4 ± 8.7 0.20 
The highest recorded BP 170.25 ± 13.05 134.75 ± 4.27 0.007
Fetus gender (male) 3 3 1.00
Values are presented as mean ± SD.
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the medium risk 1 group included pregnancies with a high 
CD44/FKBPL and low MAP, and (iv) the medium risk 2 
group included pregnancies with a low CD44/FKBPL 
ratio and high MAP (Table 6). Statistical significance was 
confined to the high-risk model where we demonstrated 
a 3.9-fold (143.6: 95% CI 1.3-11.8, P = 0.016) or 4.1-
fold (155.1: 95 CI 1.4-12.4, P = 0.013) increased risk of 
developing preeclampsia (Table 6).
The role of FKBPL and CD44 proteins in placental 
development
Endothelial dysfunction and inappropriate SUA remodeling 
by trophoblasts have been closely linked to inadequate pla-
centation and the pathogenesis of preeclampsia (35). To 
test the functional role of FKBPL in angiogenesis important 
for appropriate placental development, we transiently 
overexpressed FKBPL in HUVECs. Overexpression of 
FKBPL compared to empty vector (EV) resulted in a re-
duction of the length of tubule networks in normoxia 
(P < 0.001, n = 6; Fig.  3A). As expected, hypoxic condi-
tions demonstrated a pro-angiogenic effect, leading to 
an increase in the length of tubule networks (P = 0.024, 
n = 6; Fig. 3A, representative pictures inset), while FKBPL 
overexpression in hypoxia ameliorated this effect, restoring 
angiogenesis to normal (P < 0.001, n = 6; Fig.  3A). This 
suggests that FKBPL has a key role in hypoxia-mediated 
effects on angiogenesis.
When we investigated the functional effect of FKBPL on 
the trophoblast clonogenic potential, important for SUA 
remodeling, we showed that transient overexpression of 
FKBPL compared to EV increased the number of holoclones 
Figure 2. FKBPL expression is increased concomitantly with CD44 downregulation and VCAM-1 and ICAM-1 upregulation in preeclampsia. 
Immunofluorescence staining of placentae from women with and without preeclampsia (n = 4) was performed using an anti-FKBPL rabbit anti-
human polyclonal primary antibody (A) at a 1:150 dilution and an anti-CD31 guinea pig anti-human polyclonal primary antibody (B) at 1:50. Four 
images per slide were taken at 20× magnification and the mean fluorescence quantified using Image J (2-tailed unpaired t-test, n = 4). RNA was ex-
tracted from the frozen placental tissue, converted to complementary deoxyribonucleic acid before FKBPL and CD44 (C) or VCAM-1 and ICAM-1 (D) 
mRNA expression was measured using qPCR. The mRNA expression was adjusted to 18S and to healthy controls (n = 3; 2-way ANOVA with Sidak’s 








niversity of Technology, Sydney user on 04 February 2021
34  The Journal of Clinical Endocrinology & Metabolism, 2021, Vol. 106, No. 1
(Fig. 3B, P = 0.005 [normoxia 21% O2], P < 0.001 [hypoxia 
1% O2], n = 6) resembling stem cells, and the number of 
meroclones and paraclones resembling more differentiated 
cells (36) (Fig. 3C, P = 0.005 [normoxia 21% O2], P < 0.001 
[hypoxia 1% O2], n = 6) (37), in hypoxia or normoxia. No 
effect of hypoxia was demonstrated on BeWo holoclones 
(Fig. 3B), whereas an increase in the numbers of meroclones 
and paraclones were observed between normoxia and hyp-
oxia following transient transfection with an EV control 
plasmid (Fig. 3C, P < 0.001, n = 6).
FKBPL and CD44 as targets of emerging 
mesenchymal stem cell treatment for 
preeclampsia
Currently there are no effective therapeutic strategies for 
preeclampsia. However, a number of treatments including 
MSC-based therapies are emerging in this setting (38). 
We therefore, investigated the functional role of MSCs in 
angiogenesis and trophoblast migration important for ap-
propriate placental development. More specifically, the influ-
ence of hypoxia and MSC-conditioned medium (MSC-CM) 
on endothelial cell tubule formation and trophoblast mi-
gration, as well as the effect on FKBPL signaling, was de-
termined. Hypoxia (1%) led to an increase in the length 
of the tubule network of the HUVECs (P = 0.014, n = 6). 
MSC-CM treatment also led to an increase in the length 
of the tubule networks compared to normal or complete 
medium both under normoxic (P = 0.002, n = 6) and hyp-
oxic conditions (P = 0.02, n = 6; Fig. 4A), 6 h after seeding 
the cells in Matrigel. Overall, improved angiogenic proper-
ties were associated with reduced FKBPL protein expres-
sion following exposure to hypoxia in complete medium 
conditions (P < 0.01, n = 6) and between complete medium 
and MSC-CM conditions in normoxia (P < 0.01, n = 6; 
Fig.  4B). In hypoxia, at the mRNA level, FKBPL was re-
duced (P = 0.021, n = 3) and CD44 concomitantly in-
creased (P = 0.005, n = 3) as a result of MSC-CM treatment 
Table 3. Clinical characteristics of pregnant women at 15 and 20 weeks of pregnancy (Cohort 3)
Variable 15 Weeks of Pregnancy 20 Weeks of Pregnancy
Controls Cases P-value Controls Cases P-value
Age (years) 30.1 ± 3.6 30.2 ± 4.2 0.95 30.1 ± 3.6 30.2 ± 4.2 0.95
BMI (kg/m2) 25.8 ± 4.0 26.9 ± 5.0 0.16 n/a n/a n/a
Gestational age at delivery (weeks) 38.2 ± 13.3 37.9 ± 13.3 0.9 38.2 ± 13.3 37.9 ± 13.3 0.9
Weight change (kg) n/a n/a n/a 3.2 ± 1.9 2.9 ± 2.0 0.97
sBP (mmHg) 103.2 ± 8.9 109.8 ± 10.5 <0.001 107.7 ± 10.3 112.1 ± 10.5 0.02
dBP (mmHg) 64.9 ± 6.6 69.1 ± 7.1 <0.001 66.3 ± 6.2 70.1 ± 7.6 0.002
MAPB (mmHg) 77.7 ± 6.8 82.6 ± 7.7 <0.001 80.1 ± 7.1 84.1 ± 8.0 0.003
Random glucose (mmol/l) 5.1 ± 0.9 5.5 ± 1.2 0.049 5.4 ± 1.1 5.8 ± 1.0 0.047
CD44 (ng/mL) 115.9 ± 24.5 121.7 ± 28.7 0.23 115.3 ± 26.4 127.5 ± 30.2 0.020
FKBPL (ng/mL) 1.0 [0.59–1.30] 0.72 [0.52–1.10] 0.034 0.89 [0.61–1.16] 0.65 [0.44–1.08] 0.011
CD44/FKBPL ratio 128.8 [91.2–176.1] 143.1 [113.2–259.2] 0.018 143.1 [101.3–176.3] 181.1 [121.3–302.4] 0.004
All values are presented as mean ± SD or median with interquartile range. Two-tailed unpaired t-test (normalized distribution) or Man-Whitney (non-normalized 
distribution). All clinical characteristics were available for 128 samples in each group at 15/20 gestation (preeclampsia and healthy controls); FKBPL analysis was 
successful for 117 controls and 118 cases; CD44 analysis was successful for 120 controls and 122 cases. Bolded P-values indicate a significant difference between 
the two groups.
Abbreviations: BMI, body mass index; cases, preeclampsia; dBP, diastolic blood pressure; MAP, mean arterial blood pressure, sBP, systolic blood pressure.
Table 4. CD44/FKBPL ratio (>143.6) at 20 weeks gestation is an independent risk factor for developing preeclampsia
CD44/FKBPL ratio at 20 weeks gestation Controls Cases OR (95% CI) P-value
CD44/FKBPL ratio < 143.6 28 (51) 16 (30) 1.0a  
CD44/FKBPL ratio > 143.6 27 (49) 38 (70) 2.32 (1.03-5.23) 0.043
Clinical characteristics     
 BMI (kg/m2) 25.78 ± 4.01 26.93 ± 5.03 1.01 (0.91-1.10) 0.900
 Age (years) 30.14 ± 3.58 30.18 ± 4.16 0.98 (0.87-1.09) 0.649
 Weight change (kg) 3.19 ± 1.92 2.87 ± 2.00 0.90 (0.74-1.10) 0.319
 MAP (mmHg) 80.13 ± 7.10 84.13 ± 8.01 0.97 (0.91-1.03) 0.334
CD44/FKBPL ratios are given as n (%) for both cases and controls. All clinical characteristics are given as mean  ± SD for both cases and controls.
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of HUVECs (Fig.  4C). No differences in VCAM-1 and 
ICAM-1 mRNA expressions were observed between com-
plete medium and MSC-CM in normoxia or hypoxia.
When trophoblast cells, BeWo and Jar, were exposed 
to hypoxia and/or MSC-CM, an increase in cell migration 
was also observed in both complete medium and MSC-CM 
as a result of hypoxia (BeWo: P = 0.03 [complete; n = 3], 
P = 0.01 [MSC-CM, n = 3]; Jar: P = 0.002 [complete, 
n = 3], P < 0.001 [MSC-CM, n = 3]; Fig. 5A and 5B), and 
MSCs in normoxia (BeWo: P = 0.02, n = 3; Jar: P = 0.04, 
n = 3; Fig 5A and 5B) or hypoxia (BeWo: P = 0.008, n = 3; 
Jar: P = 0.001, n = 3; Fig 4A and 4B).
Furthermore, we used a custom made first trimester 
extravillous and endovascular trophoblast cell line, ACH-3P 
cells, which more closely resembles primary first trimester 
trophoblasts (30,39). We exposed ACH-3P cells to varying 
concentrations of oxygen (21%, 6.5%, 2.5%, and 1%), 
similar to what is observed in the first trimester during pla-
cental development (40,41), except for the 21% oxygen, 
which is above physiological levels, but extensively utilized 
in cell culture experimentation as a control. At the mRNA 
level, similar to previously described studies, FKBPL and 
CD44 expression showed opposite trends at lower oxygen 
concentrations (FKBPL: P = 0.037 [21% vs 1%]; CD44: 
P = 0.021 [21% vs 2.5%], P = 0.006 [21% vs 1%]; Fig. 5C).
These data suggest that hypoxia and MSCs have a pro-
angiogenic effect on both endothelial and trophoblast cells 
and that the mechanism targets the novel anti-angiogenic 
FKBPL-CD44 pathway. This suggest that MSCs, driven by 
their secretome, could be further explored as a potential 
novel treatment for preeclampsia.
Discussion
Currently, reliable biomarkers are lacking that can stratify 
women at high risk of developing late-onset preeclampsia 
or evolving preeclampsia between the second and third tri-
mester to enable better monitoring and early detection of 
this dangerous condition. Controlled angiogenesis is neces-
sary for appropriate placental development during preg-
nancy and any aberrant changes in the angiogenic balance 
are closely associated with preeclampsia (42).
Table 6. Odds ratio for developing preeclampsia based on the combination of MAP and the CD44/FKBPL ratio (cut-off 143.6 or 
155.1) at 20 weeks of gestation
MAP and CD44/FKBPL Controls, n (%) Cases, n (%) OR (95% CI) P-value
143.6 155.1 143.6 155.1 143.6 155.1 143.6 155.1
Low riska 16 (29) 18 (33) 7 (13) 8 (15) 1.0 1.0   
Medium risk 1b 13 (24) 11 (20) 14 (26) 13 (24) 2.46 (0.78-7.90) 2.66 (0.84-8.46) 0.130 0.098
Medium risk 2c 12 (22) 15 (27) 9 (17) 13 (24) 1.71 (0.49-5.92) 1.95 (0.64-5.95) 0.394 0.241
High riskd 14 (25) 11 (20) 24 (44) 20 (37) 3.92 (1.30-11.84) 4.09 (1.35-12.43) 0.016 0.013
Cut off value for CD44/FKBPL ratio (143.6 or 155.1) and MAP (82.5 mmHg) were determined based on the ROC analysis. Bolded P-values indicate a significant 
difference between the two groups.
Abbreviations: CI, confidence interval; OR, odds ratio.
aLow risk: Low CD44/FKBPL and low MAP (reference category).
bMedium risk 1: High CD44/FKBPL and low MAP.
cMedium risk 2: Low CD44/FKBPL and high MAP.
dHigh risk: High CD44/FKBPL and high MAP.
Table 5. CD44/FKBPL ratio (>155.10) at 20 weeks of gestation is an independent risk factor for developing preeclampsia
CD44/FKBPL ratio at 20 weeks gestation Controls Cases OR (95% CI) P-value
CD44/FKBPL ratio < 155.10 33 (60) 21 (39) 1.0a  
CD44/FKBPL ratio > 155.10 22 (40) 33 (61) 2.33 (1.05–5.17) 0.038
Clinical characteristics     
 BMI (kg/m2) 25.78 ± 4.01 26.93 ± 5.03 0.97 (0.88–1.07) 0.531
 Age (years) 30.14 ± 3.58 30.18 ± 4.16 0.94 (0.85–1.05) 0.279
 Weight change (kg) 3.19 ± 1.92 2.87 ± 2.00 0.91 (0.75–1.11) 0.354
 MAP (mmHg) 80.13 ± 7.10 84.13 ± 8.01 0.99 (0.94–1.05) 0.876
CD44/FKBPL ratios are given as n (%) for both cases and controls. All clinical characteristics are given as mean  ± SD for both cases and controls. Bolded P-values 
indicate a significant difference between the two groups.









niversity of Technology, Sydney user on 04 February 2021
36  The Journal of Clinical Endocrinology & Metabolism, 2021, Vol. 106, No. 1
This is the first study to demonstrate an important and 
novel role for the anti-angiogenic pathway, FKBPL-CD44, 
in the pathogenesis of preeclampsia, which could be 
utilized for the prediction, diagnosis, and treatment of 
preeclampsia. Our results show that the CD44/FKBPL 
ratio is associated with the risk of preeclampsia independ-
ently of established risk factors including age, BMI, MAP, 
and weight gain (33,43,44), from 20 weeks of gestation. 
Plasma FKBPL concentration was reduced at both 15 and 
20 weeks of gestation whereas plasma CD44 concentra-
tion was increased at 20 weeks of gestation in a low-risk 
cohort of women who proceeded to develop preeclampsia. 
High CD44 and low FKBPL are likely driven by hypoxia, 
which is a pro-angiogenic stimulus (45), as a result of po-
tential compensatory angiogenesis early in pregnancy. 
At 20 weeks of gestation, a high CD44/FKBPL ratio and 
high MAP were associated with an approximately 4-fold 
increased risk of preeclampsia. The early predictive value 
of clinical parameters such as maternal blood pressure in 
combination with angiogenic biomarkers has been high-
lighted previously, however mainly in preterm preeclampsia 
(43,46). The vast majority of the cases in our cohort pro-
ceeded to develop late-onset preeclampsia. Interestingly, in 
established preeclampsia, the CD44/FKBPL ratio showed 
an opposite pattern, suggesting that these potential lon-
gitudinal changes in CD44/FKBPL ratio from trimester 
2 to 3 could reflect evolving preeclampsia and, therefore, 
could be explored for early diagnosis (Fig. 6). These find-
ings in relation to a reduced the CD44/FKBPL ratio in es-
tablished preeclampsia reflective of restricted angiogenesis, 
align with previous reports of a preeclampsia-related anti-
angiogenic state where the sFlt-1/sEng ratio is increased 
and the vascular endothelial growth factor/PlGF ratio is 
decreased (47-49).
In addition to demonstrating the early biomarker po-
tential of FKBPL and CD44, we also demonstrated the key 
roles for these novel proteins in trophoblast and endothe-
lial cell function using in vitro models of SUAs remodeling 
Figure 3. FKBPL restores hypoxia-mediated angiogenic effects, and increases the colony formation in trophoblasts. (A) FKBPL was overexpressed 
using 1μg pFKBPL or an EV (pCMV3) plasmid in HUVECs for 24 h, cells were stained with calcein and trypsinized before plating 50 000 cells in 
Matrigel and exposing them to hypoxia (1%) or normoxia (21%) for 24 h. Cells were imaged using a Leica DMi8 fluorescent microscope and the 
tubules quantified using ImageJ software. Representative pictures are shown in the inset. (B and C) BeWo were seeded overnight before being trans-
fected with 1μg pFKBPL or an EV (pCMV3) control plasmid for 24 h. Following transfection, 1000 and 2000 cells were seeded in 6 well plates, allowed 
to adhere overnight, and incubated for 16 to 18 days in 21% or 1% O2 before being fixed in crystal violet 0.4% (w/v) in methanol (n = 6). Statistical ana-
lyses were performed using 1-way ANOVA with Tukey’s or Sidak’s multiple comparisons tests; n = 6. *P < 0.05, **P < 0.01, ***P < 0.001. Abbreviations: 
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important for placental development and healthy preg-
nancy. The importance of inappropriate response to low 
oxygen sensing by trophoblast cells has been previously 
linked with preeclampsia (50). Our results demonstrate 
hypoxia-mediated downregulation of FKBPL expression, 
as well as associated functional changes including mi-
gration, tubule formation, and clonogenic potential—all 
key features in placental development. Notably, hypoxia 
as a pro-angiogenic stimulus, which is present in the is-
chemic placenta in preeclampsia (51), led to a reduction 
in endothelial and trophoblast FKBPL protein and mRNA 
expressions and a concomitant increase in CD44 mRNA 
expression. These changes reflected those observed in pa-
tient plasma samples at 15 and 20 weeks of gestation in 
pregnant women, a whole trimester before the onset of 
preeclampsia. Our previous work in Fkbpl+/- knockdown 
transgenic mice indeed showed a pro-angiogenic pheno-
type; however, these mice demonstrated early signs of 
endothelial dysfunction (18). Therefore, a hypoxia-induced 
pro-angiogenic effect that drives FKBPL levels down could 
lead to endothelial dysfunction and hence the development 
of preeclampsia. Our in vitro data presented here with 
HUVECs following overexpression of FKBPL in hypoxia 
restored angiogenesis to normal levels likely preventing 
this endothelial dysfunction.
MSCs have shown therapeutic potential in various 
diseases due to their pro-angiogenic, anti-inflammatory, 
and low immunogenicity profiles. Accumulating evidence 
suggests that their beneficial effects are exerted through 
their secretome; a previous study has demonstrated that 
Figure 4. Angiogenic properties of HUVECs are improved as a result of hypoxia and mesenchymal stem cell treatment, in association with reduced 
FKBPL and increased CD44 expression. (A) HUVEC differentiation was evaluated using a tubule formation assay; cells were stained with calcein and 
trypsinized before plating 50 000 cells in Matrigel and exposing them to hypoxia (1% O2) or normoxia (21% O2) for 6 h in complete or MSC-CM medium 
(n = 6). Cells were imaged using a Leica DMi8 fluorescent microscope and the tubules quantified using ImageJ software. Representative pictures are 
shown in the inset. (B) Protein lysates were collected and Western blotting performed to determine FKBPL (42 kDa) and glyceraldehyde 3-phosphate 
dehydrogenase (37kDa) protein expressions (n = 3). FKBPL protein expression was quantified using ImageJ and adjusted to glyceraldehyde 3-phos-
phate dehydrogenase expression. A representative picture of the Western blot is shown in the inset. (C) Real-time qPCR analyses of FKBPL and CD44 
mRNA expression relative to the 18S housekeeping gene were carried out using HUVECs exposed to complete or MSC-CM in hypoxia for 24 h (n = 3). 
Results are expressed as mean ± SEM; statistical analyses were performed using 2-way ANOVA with Sidak’s or Tukey’s multiple comparisons test. 








niversity of Technology, Sydney user on 04 February 2021
38  The Journal of Clinical Endocrinology & Metabolism, 2021, Vol. 106, No. 1
MSC-conditioned media is capable of restoring angiogenic 
balance in ex vivo models of preeclampsia by reducing sFlt-1 
(52). FKBPL has not been implicated previously in MSC-
mediated pro-angiogenic and anti-inflammatory mechan-
isms of action. Recently MSCs were shown to be effective 
in reducing symptoms (ie, blood pressure and proteinuria) 
of preeclampsia using in vivo models of preeclampsia, 
mainly by targeting inflammatory mechanisms (14,15). In 
our study, we showed that MSCs are capable of enhancing 
migration of trophoblasts, in both hypoxia and normoxia, 
as well as tubule formation of endothelial cells, in associ-
ation with reduced levels of the anti-angiogenic protein, 
FKBPL, and increased pro-angiogenic CD44 mRNA ex-
pression. In our recent study, we demonstrated that in add-
ition to inhibiting angiogenesis, FKBPL is also involved in 
regulating a number of inflammatory pathways including 
signal transducer and activator of transcription 3 (20), 
which has been implicated in preeclampsia and tropho-
blast functionality (53,54). Therefore, these results suggest 
that MSCs could be utilized in established or clinically 
diagnosed preeclampsia to restore FKBPL levels to normal, 
potentially improving the vascular response and symptoms 
of preeclampsia.
While this is the first study that implicates the 
FKBPL-CD44 pathway in preeclampsia, there are some 
limitations including the small number of placental sam-
ples obtained from the Cohort 2.  However, the trend in 
FKBPL/CD44 expression levels is the same in placentae 
from Cohort 2 and plasma samples from Cohort 1, both 
of which are postdiagnosis of preeclampsia. The most 
Figure 5. Trophoblast cell migration is stimulated by hypoxia or MSC treatment and hypoxia regulates FKBPL and CD44. Migration of BeWo (A) or Jar 
(B) cells was evaluated using a wound healing scratch assay, in hypoxia (1% O2) or normoxia (21% O2), treated with complete medium or MSC-CM 
for 24 h (n = 3). (C) Real-time qPCR analyses of FKBPL and CD44 mRNA expression (n = 3) relative to the 18S housekeeping gene were performed 
in ACH-3P trophoblast cells. Results are expressed as mean ± SEM; statistical analyses were performed using 2-way ANOVA with Sidak’s or Tukey’s 
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promising prediction value of the CD44/FKBPL ratio is at 
week 20 of gestation, which is later than needed for ad-
ministration of aspirin as a preventative therapy (ie, be-
fore week 16)  (55). However, aspirin is only effective at 
preventing the risk of early-onset preeclampsia, and the 
majority of the patients from the Cohort 3 proceeded to 
develop late-onset preeclampsia. Although we did not have 
longitudinal samples from the same study before and after 
the clinical onset of preeclampsia, using separate cohorts of 
pregnant women, we demonstrated that the CD44/FKBPL 
ratio shows opposite patterns of secretion in plasma 
postdiagnosis (reflective of restricted angiogenesis) com-
pared to prediagnosis (reflective of stimulated angiogenesis, 
which could be compensatory at this stage of gestation). 
This could be beneficial for risk stratification of women 
with evolving preeclampsia and for early detection. In the 
future, CD44 and FKBPL plasma concentrations should be 
investigated in a larger cohort of patients using longitudinal 
plasma samples from all three trimesters and postdiagnosis 
of preeclampsia.
In summary, we have identified a new angiogenesis-
related pathway, FKBPL-CD44, with an important role in 
the pathogenesis of preeclampsia. Both FKBPL and CD44 
are regulated by hypoxia and appear to have key roles in 
the processes important for SUA remodeling preceding the 
onset of preeclampsia. This has both potential diagnostic 
and therapeutic applications for preeclampsia, particularly 
in relation to emerging MSC-based treatment.
Conclusion
The plasma CD44/FKBPL ratio could provide a novel risk 
stratification approach for preeclampsia at 20 weeks of 
gestation, capable of identifying women at high risk, who 
otherwise appear healthy. The CD44/FKBPL ratio could 
also identify the cases of evolving preeclampsia through lon-
gitudinal changes potentially leading to early detection of 
this condition. Similarly, the anti-angiogenic FKBPL-CD44 
axis is inhibited as part of the therapeutic mechanism of 
MSCs, which are currently in the preclinical stage of devel-
opment for the treatment of preeclampsia.
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